# TRAEMOS (NCT03784599)

> T-DM1 and Osimertinib Combination Treatment to Target HER2 Bypass Track Resistance in EGFR Mutation Positive NSCLC

No report yet. It can be ordered.

- Drugs tested: trastuzumab emtansine plus osimertinib
- Indication: EGFR mutation-positive NSCLC with HER2 bypass track resistance

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03784599
- Phase: PHASE2
- Status: TERMINATED
- Sponsor: The Netherlands Cancer Institute
- Conditions: Carcinoma, Non-Small-Cell Lung
- Interventions: Trastuzumab emtansine; Osimertinib
- Enrollment: 28
- Primary outcome: Safety (intensity and incidence of adverse events)
- Primary outcome: Objective response rate according to RECIST v1.1 after 3 months of treatment

## Indexed commentary on TRAEMOS so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=traemos-nct03784599